{"title":"Use of interleukin 12 to enhance the cellular immune response of swine to an inactivated herpesvirus vaccine.","authors":"F A Zuckermann, S Martin, R J Husmann, J Brandt","doi":"10.1016/s0065-3519(99)80034-2","DOIUrl":null,"url":null,"abstract":"<p><p>Vaccination is the single most successful medical measure against infectious disease. However, the major barrier for achieving the full protective effect or immunization is how to render attenuated, killed, or subunit vaccines as immunogenic as the fully infectious versions of these microbes (Hughes and Babiuk, 1995; Rabinovich et al., 1994). In the case of PrV, infection with wild-type virus induces an immune response superior to vaccination with a live modified vaccine. After primary intranasal infection with wild-type PrV, the replication of a homologous secondary virus challenge is completely inhibited, and the much sought \"sterile immunity\" is generated (Kimman et al., 1994). In contrast, the immune response of pigs similarly exposed to PrV mutants, which have been attenuated by removal of the thymidine kinase (TK) and the envelope glycoprotein gE gene (McGregor et al., 1985; Zuckermann et al., 1988), is insufficient for preventing the replication of a homologous wild-type virus challenge (Kimman et al., 1994). Furthermore, inactivated PrV vaccines are even less effective at inducing protective immunity than are live modified PrV vaccines (de Leeuw and Van Orischot, 1985; Stellman et al., 1989; Vannier, 1985). The importance of inactivated and subunit vaccines resides in their stability and safety, since no infectious microbe is being introduced into the animal. However, because of the recognized lower effectiveness of inactivated vaccine types, they usually fall in disfavor when a modified live vaccine alternative is available. There is a critical need to develop strategies to enhance the immunogenicity of live, inactivated, and sub-unit vaccines for human and veterinary use (Hughes and Babiuk, 1995; Rabinovich et al., 1994). Although the inoculation of an animal with a virulent microbe is obviously not the desired method to produce sterile immunity, the immune response generated to infection with wild-type PrV clearly demonstrates that this type of immunity is possible. Research directed at devising strategies to increase the immunogenicity of different types of vaccines is necessary. Because of the wealth of information available on PrV immunity (reviewed by Chinsakchai and Molitor, 1994; Nauwynck, 1997), on PrV vaccines (Kimman et al., 1992, 1994; Mettenleiter, 1991; Scherba and Zuckermann, 1996) and increasingly on the porcine immune system (Lunney, 1993; Lunney et al., 1996; Saalmüller, 1995), the swine herpesvirus model is ideal for investigating the development of vaccine formulations with enhanced immunogenicity. Among the strategies currently being examined for the enhancement of the immunogenicity of inactivated and subunit vaccines is the use of recombinant cytokines administered together with antigen (Hughes and Babiuk, 1995; Rabinovich et al., 1994). The ability to regulate the development of an immune response by cytokines such as IL-12 provides the theoretical basis to use these cytokines as adjuvants to immunopotentiate the response to an inactivated vaccine. More importantly, it provides a model to investigate the mechanisms behind the induction of protective immunity and the components of a vaccine necessary for stimulating such a response. By providing cytokines such as IL-12 or IFN-gamma in combination with the vaccine inoculum, it is reasonable to expect that they will be able to direct the differentiation of T cells during the primary immune response. Modulation, in a predictable and desired manner of the quality and quantity of the induced protective immunity, should be achievable. The ability to manipulate a vaccine-induced immune response in the direction of a predominantly cellular response (Th1-like) instead of a predominantly humoral one (Th2-like) is perhaps best illustrated by the need to develop an effective vaccine against the porcine reproductive and respiratory syndrome (PRRS) virus, whose infectivity can be significantly enhanced in vitro and in vivo by antibody induced by vaccination</p>","PeriodicalId":72111,"journal":{"name":"Advances in veterinary medicine","volume":"41 ","pages":"447-61"},"PeriodicalIF":0.0000,"publicationDate":"1999-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/s0065-3519(99)80034-2","citationCount":"43","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in veterinary medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/s0065-3519(99)80034-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 43
Abstract
Vaccination is the single most successful medical measure against infectious disease. However, the major barrier for achieving the full protective effect or immunization is how to render attenuated, killed, or subunit vaccines as immunogenic as the fully infectious versions of these microbes (Hughes and Babiuk, 1995; Rabinovich et al., 1994). In the case of PrV, infection with wild-type virus induces an immune response superior to vaccination with a live modified vaccine. After primary intranasal infection with wild-type PrV, the replication of a homologous secondary virus challenge is completely inhibited, and the much sought "sterile immunity" is generated (Kimman et al., 1994). In contrast, the immune response of pigs similarly exposed to PrV mutants, which have been attenuated by removal of the thymidine kinase (TK) and the envelope glycoprotein gE gene (McGregor et al., 1985; Zuckermann et al., 1988), is insufficient for preventing the replication of a homologous wild-type virus challenge (Kimman et al., 1994). Furthermore, inactivated PrV vaccines are even less effective at inducing protective immunity than are live modified PrV vaccines (de Leeuw and Van Orischot, 1985; Stellman et al., 1989; Vannier, 1985). The importance of inactivated and subunit vaccines resides in their stability and safety, since no infectious microbe is being introduced into the animal. However, because of the recognized lower effectiveness of inactivated vaccine types, they usually fall in disfavor when a modified live vaccine alternative is available. There is a critical need to develop strategies to enhance the immunogenicity of live, inactivated, and sub-unit vaccines for human and veterinary use (Hughes and Babiuk, 1995; Rabinovich et al., 1994). Although the inoculation of an animal with a virulent microbe is obviously not the desired method to produce sterile immunity, the immune response generated to infection with wild-type PrV clearly demonstrates that this type of immunity is possible. Research directed at devising strategies to increase the immunogenicity of different types of vaccines is necessary. Because of the wealth of information available on PrV immunity (reviewed by Chinsakchai and Molitor, 1994; Nauwynck, 1997), on PrV vaccines (Kimman et al., 1992, 1994; Mettenleiter, 1991; Scherba and Zuckermann, 1996) and increasingly on the porcine immune system (Lunney, 1993; Lunney et al., 1996; Saalmüller, 1995), the swine herpesvirus model is ideal for investigating the development of vaccine formulations with enhanced immunogenicity. Among the strategies currently being examined for the enhancement of the immunogenicity of inactivated and subunit vaccines is the use of recombinant cytokines administered together with antigen (Hughes and Babiuk, 1995; Rabinovich et al., 1994). The ability to regulate the development of an immune response by cytokines such as IL-12 provides the theoretical basis to use these cytokines as adjuvants to immunopotentiate the response to an inactivated vaccine. More importantly, it provides a model to investigate the mechanisms behind the induction of protective immunity and the components of a vaccine necessary for stimulating such a response. By providing cytokines such as IL-12 or IFN-gamma in combination with the vaccine inoculum, it is reasonable to expect that they will be able to direct the differentiation of T cells during the primary immune response. Modulation, in a predictable and desired manner of the quality and quantity of the induced protective immunity, should be achievable. The ability to manipulate a vaccine-induced immune response in the direction of a predominantly cellular response (Th1-like) instead of a predominantly humoral one (Th2-like) is perhaps best illustrated by the need to develop an effective vaccine against the porcine reproductive and respiratory syndrome (PRRS) virus, whose infectivity can be significantly enhanced in vitro and in vivo by antibody induced by vaccination
接种疫苗是预防传染病的唯一最成功的医疗措施。然而,实现完全免疫保护效果的主要障碍是如何使减毒、灭活或亚单位疫苗与这些微生物的完全感染性版本一样具有免疫原性(Hughes和Babiuk, 1995;Rabinovich et al., 1994)。就伪狂犬病毒而言,感染野生型病毒诱导的免疫反应优于接种改性活疫苗。在原发鼻内感染野生型伪病毒后,同源继发性病毒的复制被完全抑制,并产生了人们一直寻求的“无菌免疫”(Kimman等,1994)。相反,猪的免疫反应同样暴露于PrV突变体,通过去除胸苷激酶(TK)和包膜糖蛋白gE基因(McGregor et al., 1985;Zuckermann et al., 1988),不足以防止同源野生型病毒的复制(Kimman et al., 1994)。此外,在诱导保护性免疫方面,灭活伪狂犬病疫苗甚至不如改性伪狂犬病活疫苗有效(de Leeuw和Van Orischot, 1985;Stellman et al., 1989;Vannier, 1985)。灭活疫苗和亚单位疫苗的重要性在于它们的稳定性和安全性,因为没有传染性微生物被引入动物体内。然而,由于公认的灭活疫苗类型的有效性较低,当有改良的活疫苗替代时,它们通常不受欢迎。迫切需要制定战略,以提高人类和兽医使用的活疫苗、灭活疫苗和亚单位疫苗的免疫原性(Hughes和Babiuk, 1995年;Rabinovich et al., 1994)。虽然给动物接种有毒微生物显然不是产生无菌免疫的理想方法,但野生型伪狂犬病病毒感染产生的免疫反应清楚地表明,这种免疫是可能的。有必要进行旨在制定战略以提高不同类型疫苗的免疫原性的研究。因为有大量关于PrV免疫的信息(Chinsakchai和Molitor审查,1994年;Nauwynck, 1997年),关于PrV疫苗(Kimman等人,1992年,1994年;Mettenleiter, 1991;Scherba和Zuckermann, 1996),并越来越多地关注猪的免疫系统(Lunney, 1993;Lunney et al., 1996;saalmller, 1995),猪疱疹病毒模型是研究开发具有增强免疫原性的疫苗制剂的理想模型。目前正在审查的加强灭活疫苗和亚单位疫苗免疫原性的战略之一是使用重组细胞因子与抗原一起施用(Hughes和Babiuk, 1995年;Rabinovich et al., 1994)。通过IL-12等细胞因子调节免疫反应发展的能力为使用这些细胞因子作为佐剂增强对灭活疫苗的免疫反应提供了理论基础。更重要的是,它提供了一个模型来研究保护性免疫的诱导机制和刺激这种反应所需的疫苗成分。通过提供细胞因子,如IL-12或ifn - γ与疫苗接种相结合,我们有理由期望它们能够在初级免疫反应期间指导T细胞的分化。以可预测和期望的方式调制诱导保护性免疫的质量和数量应该是可以实现的。操纵疫苗诱导的免疫反应的能力主要是细胞反应(th1样),而不是主要的体液反应(th2样),可能最好的说明是需要开发一种有效的疫苗来对抗猪繁殖与呼吸综合征(PRRS)病毒,其传染性可以通过疫苗接种诱导的抗体在体外和体内显着增强